Differential assessment and management of asthma vs chronic obstructive pulmonary disease CME

MedGenMed Medscape General Medicine

Volumn 11, Issue 1, 2009, Pages

  Yawn, Barbara P ^a  

^a OLMSTED MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE DERIVATIVE; PREDNISONE; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; ANTIASTHMATIC AGENT;

AGE; ANAMNESIS; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; GENDER; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LUNG FUNCTION TEST; MEDLINE; MONOTHERAPY; ONSET AGE; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY REHABILITATION; REVIEW; SYMPTOM; COMPARATIVE STUDY; DISEASE MANAGEMENT; RISK FACTOR;

ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 59249105541     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Welte T, Groneberg DA. Asthma and COPD. Exp Toxicol Pathol. 2006;57(suppl 2):35-40. Abstract
2. National Heart Lung and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD; 2007. NIH Publication No. 07-4051.
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-555. Abstract
4. Braman SS, Kaemmerlen JT, Davis SM. Asthma in the elderly: a comparison between patients with recently acquired and long-standing disease. Am Rev Respir Dis. 1991;143:336-340. Abstract
5. Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, MD: National Heart, Lung, and Blood Institute; 2006. NIH Publication No. 02-3659.
6. Honig EG, Ingram RH. Chronic bronchitis, emphysema, and airways obstruction. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001:1491-1499.
7. Sciurba FC. Physiologic similarities and differences between COPD and asthma. Chest. 2004;126(2 suppl):117S-124S.
8. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946. Abstract
9. Beeh KM, Kornmann O, Beier J, Ksoll M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respir Med. 2004;98:591-597. Abstract
10. Boulet LP, Lemiere C, Archambault F, et al. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest. 2006;129:661-668. Abstract
11. Brinke AT, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164:744-748. Abstract
12. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645-1648. Abstract
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-187. Abstract
14. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160:1683-1689. Abstract
15. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J. 1999;14:892-896. Abstract
16. Vonk JM, Jongepier H, Panhuysen CIM, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58:322-327. Abstract
17. Rudd RA, Moorman JE. Asthma incidence: data from the national health interview survey, 1980-1996. J Asthma. 2007;44:65-70. Abstract
18. Influenza vaccination coverage among children with asthma - United States, 2004-05 influenza season. MMWR Morb Mortal Wkly Rep. 2007;56:193-196. Abstract
19. American Lung Association. Trends in Asthma Morbidity and Mortality. New York, NY: American Lung Association Epidemiology & Statistics Unit; 2006.
20. Brunner WM, Lindgren PG, Langner DM, Williams AN, Yawn BP. Asthma among rural Minnesota adolescents. J Asthma. 2005;42:787-792. Abstract
21. National Heart Lung and Blood Institute. Morbidity and Mortality Chartbook. Bethesda, MD: US Department of Health and Human Services; 2004.
22. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol. 2003;112:819-827; quiz, 828.
23. American Thoracic Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900. Abstract
24. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration. 2001;68:4-19. Abstract
25. Ekici A, Ekici M, Kurtipek E, et al. Obstructive airway diseases in women exposed to biomass smoke. Environ Res. 2005;99:93-98. Abstract
26. American Lung Association. Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality American Lung Association epidemiology & statistics unit research and program services; 2007.
27. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ. 2002;51:1-16.
28. Hoyert DL, Heron MP, Murphy SL, Kung HC. Deaths: final data for 2003. Natl Vital Stat Rep. 2006;54:1-120.
29. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Available at: www.ginasthma.org/download.asp?intId=215 Accessed November 21, 2007.
30. Jenkins MA, Hopper JL, Bowes G, et al. Factors in childhood as predictors of asthma in adult life. BMJ. 1994;309:90-93. Abstract
31. van Schayck CP, Levy ML, Chen JC, Isonaka S, Halbert RJ. Coordinated diagnostic approach for adult obstructive lung disease in primary care. Prim Care Respir J. 2004;13:218-221. Abstract
32. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.com/ Guidelineitem.asp?l1=2&l2=1&intId=989 Accessed April 14, 2008.
33. American Lung Association. ALA Asthma Survey: Executive Summary. Available at: http://www.lungusa.org/site/apps/s/ content.asp?c=dvLUK9O0E&b=34706&ct=67427 Accessed November 21, 2007.
34. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest. 2008;133:19-25. Abstract
35. Groenewegen KJ, Postma DS, Hop WC, Wielders PL, Schlosser NJ, Wouters EF. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008;133:350-357. Abstract
36. Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med. 2008;121:789-796. Abstract
37. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28:1245-1257. Abstract
38. Decramer M, Selroos O. Asthma and COPD: differences and similarities. With special reference to the usefulness of budesonide/formoterol in a single inhaler (Symbicort) in both diseases. Int J Clin Pract. 2005;59:385-398. Abstract
39. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(10 Pt 2):S28-S38.
40. Rogers DF. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis. 2000;55:324-332. Abstract
41. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:20-22. Abstract
42. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31:742-750. Abstract
43. Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58:659-664. Abstract
44. Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of Ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999;115:966-971. Abstract
45. Mallia P, Contoli M, Caramori G, et al. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. Curr Pharm Des. 2007;13:73-97. Abstract
46. Pauwels RA. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc. 2004;1:73-76. Abstract
47. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:367-370; discussion, 371-372.
48. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370:797-799.
49. Yawn BP, Kaplan A. Co-morbidities in people with COPD: a result of multiple diseases, or multiple manifestations of smoking and reactive inflammation? Prim Care Respir J. 2008. [Epub ahead of print].
50. Pierce R. Spirometry: an essential clinical measurement. Aust Fam Physician. 2005;34:535-539. Abstract
51. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-338. Abstract
52. Aggarwal AN, Agarwal R. The new ATS/ERS guidelines for assessing the spirometric severity of restrictive lung disease differ from previous standards. Respirology. 2007;12:759-762. Abstract
53. Boulet LP, Turcotte H, Hudon C, Carrier G, Maltais F. Clinical, physiological and radiological features of asthma with incomplete reversibility of airflow obstruction compared with those of COPD. Can Respir J. 1998;5:270-277. Abstract
54. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:418-424. Abstract
55. Saydain G, Beck KC, Decker PA, Cowl CT, Scanlon PD. Clinical significance of elevated diffusing capacity. Chest. 2004;125:446-452. Abstract
56. Liem JJ, Kozyrskyj AL, Cockroft DW, Becker AB. Diagnosing asthma in children: what is the role for methacholine bronchoprovocation testing? Pediatr Pulmonol. 2008;43:481-489.
57. Anderson SD. Provocative challenges to help diagnose and monitor asthma: exercise, methacoline, adenosine, and mannitol. Curr Opin Pulm Med. 2008;14:39-45. Abstract
58. Birnbaum S, Barreiro TJ. Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement. Chest. 2007;131:1932-1935. Abstract
59. Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc. 2006;3:176-179.
60. Chang J, Mosenifar Z. Differentiating COPD from asthma in clinical practice. J Intensive Care Med. 2007;22:300-309. Abstract
61. Dewar M, Curry RW Jr. Chronic obstructive pulmonary disease: diagnostic considerations. Am Fam Physician. 2006;73:669-676. Abstract
62. Mauad T, Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008;14:31-38. Abstract
63. Sverzellati N, Molinari F, Pirronti T, et al. New insights on COPD imaging via CT and MRI. Int J Chron Obstruct Pulmon Dis. 2007;2:301-312. Abstract
64. Tonnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2007;29:390-417. Abstract
65. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-1505. Abstract
66. Paz-Diaz H, Montes de Oca M, Lopez JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil. 2007;86:30-36. Abstract
67. Guell R, Resqueti V, Sangenis M, et al. Impact of pulmonary rehabilitation on psychosocial morbidity in patients with severe COPD. Chest. 2006;129:899-904. Abstract
68. Foglio K, Bianchi L, Bruletti G, et al. Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. Respir Med. 2007;101:1961-1970. Abstract
69. Rochester CL. Exercise training in chronic obstructive pulmonary disease. J Rehabil Res Dev. 2003;40(5 Suppl 2):59-80.
70. McFadden ER. Asthma. In: Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001:1457-1463.
71. Marcus P. Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest. 2006;129:466-474. Abstract
72. Fahy JV. Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol. 2006;17:1230-1232.
73. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-465. Abstract
74. Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care. 2007;52:833-851. Abstract
75. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-784. Abstract
76. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965. Abstract
77. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216. Abstract
78. Calverley PM. Respiratory failure in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003;47:26s-30s. Abstract